Spyre Therapeutics (SYRE) Change in Receivables (2015 - 2023)
Spyre Therapeutics posted quarterly Change in Receivables of -$163000.0 for Q4 2023, up 44.56% year-on-year from -$112757.6 in Q4 2022, and up 89.01% on a QoQ basis from -$1.5 million in Q3 2023.
Spyre Therapeutics (SYRE) has 7 years of Change in Receivables data on file, last reported at -$163000.0 in Q4 2023.
- For the quarter ending Q4 2023, Change in Receivables rose 44.56% year-over-year to -$163000.0; the trailing twelve-month figure through Sep 2024 stood at -$163000.0 (up 67.79% YoY), and the FY2023 full-year result was -$375000.0, up 14.77% from the prior year.
- Change in Receivables for Q4 2023 stood at -$163000.0, up from -$1.5 million in the prior quarter.
- Across five years, Change in Receivables topped out at $21.5 million in Q1 2021 and bottomed at -$21.5 million in Q2 2021.
- The 3-year median for Change in Receivables is -$45000.0 (2023), against an average of $0.0.
- Peak annual rise in Change in Receivables reached 346.9% in 2023, while the deepest fall reached 880.53% in 2023.
- A 3-year view of Change in Receivables shows it stood at $815000.0 in 2021, then sank by 136.07% to -$294000.0 in 2022, then surged by 44.56% to -$163000.0 in 2023.
- The last three Change in Receivables figures came in at -$163000.0 (Q4 2023), -$1.5 million (Q3 2023), and $1.3 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 208,524.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -39.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -1.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 110.42 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -163,000.00 |
| Dec 31, 2023 | -163,000.00 |
| Sep 30, 2023 | -1.48 Mn |
| Sep 30, 2023 | -1.48 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Jun 30, 2023 | 1.32 Mn |
| Mar 31, 2023 | -45,000.00 |
| Mar 31, 2023 | -45,000.00 |
| Dec 31, 2022 | -294,000.00 |
| Dec 31, 2022 | -294,000.00 |
| Sep 30, 2022 | 190,000.00 |
| Sep 30, 2022 | 190,000.00 |
| Jun 30, 2022 | -533,000.00 |
| Jun 30, 2022 | -533,000.00 |
| Mar 31, 2022 | 197,000.00 |
| Mar 31, 2022 | 197,000.00 |
| Dec 31, 2021 | 815,000.00 |
| Dec 31, 2021 | 815,000.00 |
| Jun 30, 2021 | -21.50 Mn |
| Jun 30, 2021 | -21.50 Mn |
| Mar 31, 2021 | 21.50 Mn |
| Mar 31, 2021 | 21.50 Mn |
| Dec 31, 2018 | -2.42 Mn |
| Dec 31, 2018 | -2.42 Mn |
| Sep 30, 2018 | -1.86 Mn |
| Sep 30, 2018 | -1.86 Mn |
| Jun 30, 2018 | 908,000.00 |
| Jun 30, 2018 | 908,000.00 |
| Mar 31, 2018 | 295,000.00 |
| Mar 31, 2018 | 295,000.00 |
| Dec 31, 2017 | 626,000.00 |
| Dec 31, 2017 | 626,000.00 |
| Sep 30, 2017 | 1.24 Mn |
| Sep 30, 2017 | 1.24 Mn |
| Jun 30, 2017 | 232,000.00 |
| Jun 30, 2017 | 232,000.00 |
| Mar 31, 2017 | -234,000.00 |
| Mar 31, 2017 | -234,000.00 |
| Dec 31, 2016 | -356,000.00 |
| Dec 31, 2016 | -356,000.00 |
| Sep 30, 2016 | -54,000.00 |
| Sep 30, 2016 | -54,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Jun 30, 2016 | 7,000.00 |
| Mar 31, 2016 | -79,000.00 |
| Mar 31, 2016 | -79,000.00 |
| Dec 31, 2015 | -2.54 Mn |
| Dec 31, 2015 | -2.54 Mn |
| Sep 30, 2015 | 808,000.00 |
| Sep 30, 2015 | 808,000.00 |